Thymus regeneration promotes naïve T-cell recovery in iMycTg aging-E mice and a partial decrease in Treg frequencies. by Abigail Morales-Sánchez (21799582)

DALY and HLY in Portugal, 1990–2019. The first graph shows a decreasing trend of DALY and the second graph shows an increasing trend of HLY. by Aida Isabel Tavares (12080156)

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

Subjects:

Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in oxidative stress levels. by Qi He (384033)

Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in lipid peroxidation levels. by Qi He (384033)

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Therapeutic drug monitoring should be performed in vulnerable populations, such as the elderly, children, and infants, to improve efficacy and reduce toxicity. Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. …”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Therapeutic drug monitoring should be performed in vulnerable populations, such as the elderly, children, and infants, to improve efficacy and reduce toxicity. Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. …”

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

The cleft width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

The number, age, and weight of the patients with cleft lip and palate in the velar adhesion VA group and non-VA group. by Miki Kashiwagi (21439684)

Subjects:

Measurement of the patients’ dental cast models. by Miki Kashiwagi (21439684)

Subjects:

The dental arch length at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

The alveolar width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

Velar adhesion (VA). by Miki Kashiwagi (21439684)

Subjects:

(A) The incidence of OME in the VA group compared to the non-VA group. (B) The rate of tympanostomy tube insertion in the VA group and non-VA group. by Miki Kashiwagi (21439684)

Subjects:

The dental arch width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects: